Bellevue Asset Management has launched a new healthcare fund specifically focused on emerging market innovations, Citywire Switzerland can reveal.
The Bellevue Funds (Lux) – BB Adamant Emerging Markets Healthcare fund will be managed by Cyrill Zimmermann and Oliver Kubli.
The fund is designed to offer defensive access to a market segment with structural growth characteristics in a region with significant healthcare sector growth.
The new fund will tap long-term trends such as demographics and aging. The biggest country allocations are currently China (38%), Korea (26%) and Brazil (13%).
One of the Chinese stocks investing in is Tonghua Dongbao Pharma, which focuses on integrated diabetes solutions, such as orals, human insulin, blood sugar measurement/monitoring and online platforms.
At a sector level the strategy allocates most heavily to generics (44%) and medtech (29%). The official benchmark of the fund is MSCI Emerging Markets Healthcare Index.
The BB Adamant team looks after CHF 1.2 billion of assets across different strategies and does a global research of 3,000 companies.